Iterum Therapeutics plc (ITRMF) Income towards Parent Company (2017 - 2025)

Iterum Therapeutics has reported Income towards Parent Company for 9 years, with the latest figure at -$9.0 million in Q3 2025.

• On a quarterly basis, Income towards Parent Company fell 47.34% year-over-year to -$9.0 million in Q3 2025; TTM through Sep 2025 was -$24.0 million, a 10.9% increase from a year earlier, with the FY2024 full-year figure at -$21.8 million, up 37.22% from the prior year.
• Income towards Parent Company was -$9.0 million for Q3 2025 at Iterum Therapeutics, down from -$6.5 million in the prior quarter.
• The five-year high for Income towards Parent Company was $7.9 million in Q4 2021, with the low at -$98.9 million in Q1 2021.
• Average Income towards Parent Company over 5 years is -$10.3 million, with a median of -$6.1 million recorded in 2024.
• The sharpest annual moves came in 2021 and 2023: Income towards Parent Company surged 266.56% in 2021, then plunged 1304.95% in 2023.
• Over 5 years, Income towards Parent Company stood at $7.9 million in 2021, then tumbled by 90.76% to $728000.0 in 2022, then slumped by 1304.95% to -$8.8 million in 2023, then jumped by 58.45% to -$3.6 million in 2024, then slumped by 146.34% to -$9.0 million in 2025.
• The last three Income towards Parent Company figures came in at -$9.0 million (Q3 2025), -$6.5 million (Q2 2025), and -$4.9 million (Q1 2025), per Business Quant data.